Company Overview - TOP Financial Group Limited is a fast-growing online brokerage firm based in Hong Kong, specializing in trading local and foreign equities, futures, options products, and other financial services [1][3] - The company has relocated its headquarters to Singapore, which is recognized as a major financial center with stable political policies, economic growth, and a low tax rate [2] Strategic Expansion - The relocation to Singapore is part of the company's strategic expansion plan to explore new business opportunities in Southeast Asia [2] - TOP Financial Pte Ltd., a subsidiary of the company, obtained a capital market services (CMS) license from the Monetary Authority of Singapore in June 2025, enhancing product diversification and investor flexibility [2][4] Services Offered - The company provides a range of diversified services through its operating subsidiaries, including online brokerage platforms, asset and funds management, trading solutions, money lending, trust services, and investor relations [3][4] - The operating subsidiaries are licensed with the Securities and Futures Commission of Hong Kong to conduct various regulated activities, including dealing in securities and futures contracts [4] Recent Acquisitions - TOP Financial Group has completed the acquisition of an Australia licensed company, TOP 500 Sec Pty Ltd, which will enable it to provide dealing services in derivatives and foreign exchange contracts [4] - The company has also acquired Zhong Yang Financial Services Limited, which will offer investor relations and public relations services, and is in the process of acquiring a TCSP license in Hong Kong [4]

TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce its financial results for the three months ended June 30, 2025. The Company reported continued revenue growth in the second quarter of 2025, up 248% from Q2 2024, while cost of revenues were up only 60% during the same time period, maintaining the Company’s high operating leverage. Seco ...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). ...

Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and d ...

Core Insights - OneMedNet Corporation has achieved significant adoption by a leading global medical device company, recognized for its advancements in diagnostic imaging and digital health solutions [1] - The company has established a master services agreement that allows for ongoing engagement without a fixed term, including multiple purchase orders for Real-World Data [2] - OneMedNet's ability to provide comprehensive, multimodal data sets is emphasized as a key factor in generating Real-World Evidence, which is crucial for AI model development in medical imaging [3] Company Overview - OneMedNet is positioned as a leader in harnessing Real-World Data (RWD) through its iRWD™ platform, which taps into data from over 1,750 healthcare sites [5] - The company focuses on delivering curated, de-identified datasets that empower clients to enhance AI development, clinical trial design, and healthcare outcomes [4] - Beyond healthcare, OneMedNet's proprietary AI technology is applicable in other industries such as finance, retail, and telecom, showcasing its versatility [6]

Safety and Pharmacokinetic Data Support Dosing ofART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological co ...

Core Viewpoint - MannKind Corporation has signed a definitive merger agreement to acquire scPharmaceuticals Inc, marking a strategic expansion into cardiorenal medicine and enhancing its cardiometabolic business alongside its orphan lung division [1][2]. Strategic and Financial Benefits - The acquisition is expected to diversify and accelerate double-digit revenue growth, particularly through FUROSCIX, which addresses significant unmet needs in chronic heart failure and chronic kidney disease [6][7]. - MannKind will pay an upfront cash of $5.35 per share, representing a 36% premium to scPharmaceuticals' 90 trading day VWAP, with total consideration potentially reaching $6.35 per share [6][9]. - The total equity value of the transaction is approximately $303 million, with a total deal value of up to $360 million, expected to close in Q4 2025 [9]. Commercial Momentum - scPharmaceuticals has shown strong commercial momentum, with net sales of $27.8 million for the first half of 2025, reflecting a 96% year-over-year increase [3]. - The FUROSCIX ReadyFlow Autoinjector is on track for a supplemental New Drug Application submission in Q3 2025, which could significantly reduce treatment time for patients [3][6]. Revenue Diversification - The combined company will have a stronger revenue base with three commercial assets: Afrezza, FUROSCIX, and V-Go, leading to an annualized run rate of over $370 million based on Q2 2025 results [7]. - MannKind anticipates double-digit annual growth from its commercial products, supported by upcoming product launches and indication expansions [7][8]. Integration and Growth Opportunities - The integration of scPharmaceuticals' established commercial and medical capabilities into MannKind's infrastructure is expected to unlock meaningful growth opportunities [6][8]. - MannKind's existing strengths in endocrinology and scPharmaceuticals' expertise in cardiovascular care will enhance the market opportunity for FUROSCIX in chronic kidney disease [8].

MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent corporate developments and forecast for 2025/26. As a result of completing a recent initial public offering and up-listing to Nasdaq, the Company is entering a transformational stage as it prepares for the adv ...

Recent Purchases include 1,111 ETH at an Average Price of $4,341 Charlotte, NC, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fundamental Global Inc (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”), today announced its current ETH position increased to 48,545 ETH as of August 25, 2025, following a series of additional purchases and reflecting the positive impact of the Company’s initial staking rewards. The Company’s total ETH holdings are 48,545 representing approximately $230 million in an aggregate value (assumin ...

TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B advance from Vantive US Healthcare LLC (“Vantive”) pursuant to the previously disclosed senior secured promissory note entered into in May 2025. The Tranche B advance further strengthens Spectral’s balance sheet and will be used to support ongoing r ...